A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan

Wen Cheng Chang, Amy Y. Lin, Jason C. Hsu, Chiao En Wu, Connie Goh, Patrick Chou, Kaitlin Kuo, Anne Chang, Roberto Palencia

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)


Background: Metastatic Merkel cell carcinoma (mMCC) has traditionally been managed with palliative chemotherapy regimens or best supportive care (BSC). Avelumab, a novel anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody for mMCC treatment, is being studied in the pivotal JAVELIN Merkel 200 trial. Aim: Incorporating trial results, this analysis aimed to evaluate the cost-utility of avelumab in Taiwan. Methods and results: A de novo partitioned-survival model with three key health states related to survival (progression-free disease, progressed disease, and death) was applied in this study. The data of clinical efficacy, safety, and patient utilities were obtained from the JAVELIN Merkel 200 trial, literature review, and Taiwanese clinical expert opinion. Cost-utility analysis was performed, and results were presented as cost per quality-adjusted life year (QALY) gained. For treatment-naïve patients, the incremental cost-effectiveness ratios (ICERs) for avelumab vs BSC and avelumab vs chemotherapy were US$44885.06 and US$42993.06 per QALY gained, respectively. As to treatment-experienced mMCC patients, avelumab was associated with ICERs of US$27243.06 (vs BSC)/US$26557.43 (vs chemotherapy) per QALY gained. All ICERs remained consistently within the willingness-to-pay (WTP) threshold of US$53,333.33 per QALY gained. Conclusion: This study demonstrated avelumab to be a cost-effective treatment option for both treatment-experienced and treatment-naïve mMCC patients with very poor prognosis in Taiwan.

期刊Cancer Reports
出版狀態已發佈 - 12月 2021

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究


深入研究「A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan」主題。共同形成了獨特的指紋。